RecruitingPhase 3NCT06996080
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
Studying Medullary sponge kidney
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kodiak Sciences Inc
- Intervention
- KSI-101(drug)
- Enrollment
- 150 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (30)
- Research Network Arizona, Scottsdale, Arizona, United States
- Global Research Management, Inc., Glendale, California, United States
- UCLA Stein Eye Institute, Los Angeles, California, United States
- Stanford Byers Eye Institute, Palo Alto, California, United States
- California Eye Specialists Medical Group, Inc., Pasadena, California, United States
- California Eye Specialists Medical Group, Inc., Redlands, California, United States
- Retina Consultants of Southern California, Redlands, California, United States
- Retinal Consultants Medical Group Inc, Sacramento, California, United States
- Retina Group of New England, PC, Waterford, Connecticut, United States
- Retina Group of Florida (Ft. Lauderdale), Fort Lauderdale, Florida, United States
- Associated Vitreoretinal and Uveitis Consultants LLC, Carmel, Indiana, United States
- Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
- Retina Consultants of Minnesota, Saint Louis Park, Minnesota, United States
- The Retina Institute, St Louis, Missouri, United States
- Retina Associates of New York, P.C., New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06996080 on ClinicalTrials.govOther trials for Medullary sponge kidney
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07489131Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular EdemaAlvotech Swiss AG
- RECRUITINGPHASE2NCT07441642A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationNovartis Pharmaceuticals
- ENROLLING BY INVITATIONPHASE2NCT07395986A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related CataractOcusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
- RECRUITINGPHASE2NCT07400965Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex BlepharitisGlaukos Corporation
- RECRUITINGPHASE3NCT07235085A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic RetinopathyOcular Therapeutix, Inc.
- RECRUITINGPHASE2NCT07128628A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseaseBausch & Lomb Incorporated
- RECRUITINGPHASE3NCT06990399A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKKodiak Sciences Inc
- RECRUITINGPHASE3NCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration4D Molecular Therapeutics